Abstract
(-)-Agelastatin A (AA) in 1,2-propanediol (3-deoxy-DL-glycerol) elicits a dose-dependent decrease in OPN mRNA expression in canine Duchenne Muscular Dystrophy (DMD) myoblasts at doses ranging from 0.01 nM-30 nM. When intraperitoneally administered in the same vehicle to mdx mice at 2.5 mg/kg/day for two weeks, and at 1.5 mg/kg/day twice-weekly for two weeks, (-)-AA brings about a significant decrease in exercise-induced muscle damage through its attenuation of OPN expression. Because (-)-AA is known to downregulate OPN, this study confirms that the use of small molecule OPN downregulatory drugs can beneficially modify the phenotype in DMD animal models and potentially affected boys.
Original language | English |
---|---|
Type | Preprint |
Media of output | Preprint Server |
Publisher | ChemRxiv |
Number of pages | 9 |
DOIs | |
Publication status | Published - 16 Mar 2021 |
Keywords
- Osteopontin, β-catenin, (-)-agelastatin A, Duchenne muscular dystrophy (DMD), canine myoblasts, mdx mice
Fingerprint
Dive into the research topics of 'Osteopontin (OPN) Downregulatory Alkaloid (-)-Agelastatin A Prevents Muscle Damage in a Mouse Model of Duchenne Muscular Dystrophy'. Together they form a unique fingerprint.Student theses
-
Further investigations into the mechanism of the o-directed free radical hydrostannation of alkyl and aryl acetylenes
Watson, H. (Author), Stevenson, P. (Supervisor) & Hale, K. (Supervisor), Jul 2022Student thesis: Doctoral Thesis › Doctor of Philosophy
File